New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists
about
The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedureHeteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.Neural control of the lower urinary tractIdentification of zebrafish A2 adenosine receptors and expression in developing embryosDifferential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism.The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonistsEffect of the adenosine A2A receptor antagonist MSX-3 on motivational disruptions of maternal behavior induced by dopamine antagonism in the early postpartum ratDifferential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism.Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intakeDual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseDopamine, behavioral economics, and effort.Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket.Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice.Systematic protein-protein interaction mapping for clinically relevant human GPCRsThe behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.Central nervous targets for the treatment of bladder dysfunction.Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy.Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.New Frontiers of Basic Science Research in Neurogenic Lower Urinary Tract Dysfunction.Molecular docking studies of 1-(substituted phenyl)-3-(naphtha [1, 2-d] thiazol-2-yl) urea/thiourea derivatives with human adenosine A(2A) receptor.Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats.Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use.Adenosine A2A receptors are up-regulated in Pick's disease frontal cortex.Antiparkinsonian Effects of Novel Adenosine A2A Receptor Antagonists
P2860
Q24607362-95ED2512-5D75-45C9-BC3B-9623D1A16AA7Q24630645-9C14CF56-BC4A-483A-AB7D-1F4F44223D3BQ26828785-AC2A6126-27CE-4902-9248-AEE6583A695CQ30436906-F39FED09-26F1-4952-B7AB-51371571E597Q33591276-860696AF-43A9-4004-A7AE-1C56936369D6Q33591302-8A626B03-F85E-4FD0-9242-6C46C32B37D9Q33872174-68544560-4F3A-4062-A397-EA907ADC0C82Q34802194-1C495336-1F50-4EF3-A157-8443508E032EQ35706890-3F19264C-CF1F-430E-A350-846DFC80C1ADQ36250876-134A989A-670B-4C2F-A7B5-B01600C5D87AQ37172329-44079AAD-AFC4-4785-BB3A-8C754557C957Q37358676-1A51B00D-4BB2-4A78-98DC-338761321E1CQ37614233-8E7C13E0-7B92-4012-B585-A48B3730E21BQ37682278-DDD299FA-838D-4AE3-96A1-E21342B8E33DQ37712460-E62B27A7-4B69-4FA6-A93B-044E4EC22291Q37727700-F5ECDA49-6980-403A-A4ED-3EBB8563C780Q37979784-CD777266-7E90-48B7-9902-CEDE685BCBF1Q38119899-AB4083C5-6947-43BB-9EED-5A6024BB44C9Q39037307-7618FAC9-FB84-47D8-853A-3E9E1EEEF15AQ39432789-2708BD4A-2152-4A10-A279-B9E621B803B3Q39439674-92C82149-9778-4143-8719-3603DC1C53E4Q41908900-5697742C-F910-4F36-918A-729A301217B2Q42135362-D3BD78B7-75E2-49A8-85E1-6504D532E11EQ43180394-3C318424-5A48-4797-B6A1-99EF4EEEA54AQ47851272-3CC40A62-EAB2-434E-A7E2-EE79452F544EQ48369377-2A59880C-7035-4BD0-A6FB-76E21A4D3FC9Q57708302-50B309E1-4612-4FA1-94D9-1F23A1D98EB6
P2860
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
New therapies for the treatmen ...... osine A2A receptor antagonists
@ast
New therapies for the treatmen ...... osine A2A receptor antagonists
@en
New therapies for the treatmen ...... osine A2A receptor antagonists
@nl
type
label
New therapies for the treatmen ...... osine A2A receptor antagonists
@ast
New therapies for the treatmen ...... osine A2A receptor antagonists
@en
New therapies for the treatmen ...... osine A2A receptor antagonists
@nl
prefLabel
New therapies for the treatmen ...... osine A2A receptor antagonists
@ast
New therapies for the treatmen ...... osine A2A receptor antagonists
@en
New therapies for the treatmen ...... osine A2A receptor antagonists
@nl
P50
P1433
P1476
New therapies for the treatmen ...... osine A2A receptor antagonists
@en
P304
P356
10.1016/J.LFS.2005.04.029
P407
P577
2005-11-12T00:00:00Z